Ivonescimab in Comb. With FOLFOX in Advanced HER2 Neg. GEA
Ivonescimab in Comb. With FOLFOX in Advanced HER2 Neg. GEA
Recruiting · NCT07070466 · Registry updated 2026-08-28Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Ivonescimab in Comb. With FOLFOX in Advanced HER2 Neg. GEA | Digestive System Diseases, Digestive System Neoplasms, Esophageal Neoplasms, Head and Neck Neoplasms, Neoplasms by Site, digestive system disorder, digestive system neoplasm, esophageal cancer, esophageal disorder, gastric cancer, gastric neoplasm, neoplasm, stomach disorder | Recruiting | Phase 2 | 2026-08-28 | NCT07070466 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Massachusetts General Hospital | 758 |
| Summit Therapeutics | 31 |
2 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Massachusetts General Hospital | Boston | United States | 1015 |
| UCLA | Santa Monica | United States | 14 |